安博维—优秀的一线抗高血压药物演示课件.pptVIP

幻灯片36. 安博维和氨氯地平的降压疗效 在181例轻中度高血压(平均基线SeDBP为99.7mmHg)患者中进行了为 期4周的随机双盲试验，安博维组服用150mg，氨氯地平组服用5mg (Neutel J et al. Am J Hypertens. 1999;12:128A）。 治疗 4 周时安博维组 和氨氯 地平组SeDBP的降低幅度(分别为－9.4和－9.6mmHg)无统计 学差异。 安博维组和氨氯地平组SeSBP的降低幅度相似(治疗4周 时分别为 －12.2和－12.4mmHg)。 因此，对轻中度高血压患者的治疗，安博维是一种安全有效的一线药物，对血压的降低幅度与氨氯地平相似。 Mancia et al performed another study comparing irbesartan with valsartan with regard to BP control, using ABPM, self-measurement, and office measurement. The study was designed to compare the two agents’ relative ability to reduce ambulatory BP. For this study, 426 patients were randomized to receive either irbesartan 150 mg or valsartan 80 mg for 8 weeks. At Week 8, the reduction in trough ambulatory DBP (ADBP) was significantly greater with irbesartan, compared with valsartan (-6.7 vs. -4.8 mmHg, respectively; p=0.035). The reduction in trough ambulatory systolic blood pressure (ASBP) was also significantly greater for irbesartan than for valsartan (-11.6 vs. -7.5 mmHg, respectively; p0.01). Both drugs were well-tolerated. Background The primary objective of this study was to compare the change from baseline in mean diastolic ambulatory blood pressure (ABP) at 24 hours post dose (trough measurement) after eight weeks of treatment with irbesartan or valsartan in subjects with mild-to-moderate hypertension. Secondary objectives included comparing the mean changes from baseline in systolic ABP at trough; 24-h ABP; morning and night-time ABP; self-measured systolic blood pressure (SBP) and diastolic blood pressure (DBP); and office-measured SBP and DBP at trough. Design After a three-week, single blind, placebo lead-in period, 426 subjects were randomized to receive either irbesartan 150 mg or valsartan 80 mg for eight weeks. Methods Ambulatory blood pressure measurements were obtained at baseline and at Week 8. Self-measured morning and evening DBP and SBP readings were obtained at home over a seven-day period at baseline and at Week 8. Office-measured seated DB